Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
Vaxart, Inc. SVP and General Counsel Edward B. Berg received new equity awards as part of his compensation. On March 16, 2026, he was granted 115,000 shares of common stock upon vesting of restricted stock units, with 25% of the units vesting on each anniversary of the March 16, 2026 vesting commencement date until fully vested after four years.
He was also granted a stock option for 225,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments so it is fully vested by March 16, 2030. Following these grants, Berg directly holds 799,858 common shares.
Vaxart, Inc. files its Annual Report describing progress on its oral tablet vaccine pipeline and regulatory environment. The company focuses on norovirus, COVID-19, influenza and HPV using its VAAST oral adenovirus-based platform to induce mucosal and systemic immunity via enteric‑coated tablets.
Vaxart reports positive Phase 1 data for a second‑generation bivalent norovirus vaccine showing large increases in functional antibodies and fecal IgA, and outlines plans to advance development with additional funding or partners. It also details a large BARDA‑funded Phase 2b COVID‑19 booster study using an oral KP.2‑targeted candidate versus an approved mRNA comparator, where about 5,400 adults were enrolled before U.S. authorities halted further enrollment but allowed 12‑month follow‑up to continue under a contract currently funded up to $316.0 million.
The filing further reviews prior BARDA‑funded influenza challenge data, an early HPV therapeutic vaccine program, in‑house and outsourced GMP manufacturing capabilities, extensive U.S. and foreign regulatory requirements, and a competitive landscape where no vaccines yet exist for norovirus or HPV therapy. As of June 30, 2025, non‑affiliate market value of common stock was $102,712,906 at $0.45 per share, and 240,634,372 shares were outstanding as of March 6, 2026.
Vaxart reported a strong turnaround for 2025, moving to profitability and highlighting progress in its oral vaccine pipeline. Revenue rose to $237.3 million from $28.7 million in 2024, driving net income of $16.3 million versus a prior-year net loss of $66.9 million. Earnings were $0.07 per basic and diluted share.
The company ended 2025 with cash, cash equivalents and investments of $63.8 million and stated it has runway into the second quarter of 2027. Vaxart highlighted a worldwide collaboration with Dynavax for its COVID-19 oral pill vaccine and expects topline data from a 400-person Phase 2b sentinel cohort in early Q2 2026, with full efficacy and safety readout from about 5,000 participants expected in the fourth quarter of 2026. The company also reported positive norovirus vaccine data in lactating women showing passive antibody transfer to infants.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported an automatic share withholding tied to restricted stock units (RSUs). On February 2, 2026, 7,965 shares of common stock were withheld at $0.6085 per share to satisfy income tax obligations upon RSU vesting. After this transaction, he beneficially owned 737,792 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. The transaction was reported as directly held ownership.
Vaxart, Inc. SVP and General Counsel Edward B. Berg reported a routine tax-related share withholding. On February 2, 2026, 9,265 shares of common stock were withheld at $0.6085 per share to cover income tax obligations from vested RSUs. After this transaction, Berg directly beneficially owned 684,858 common shares, which includes 70,781 shares acquired through Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. senior vice president and chief scientific officer Sean Tucker reported a routine share withholding tied to restricted stock units (RSUs). On February 2, 2026, 9,265 shares of Vaxart common stock were withheld by the company at $0.6085 per share to cover income tax obligations upon RSU vesting.
After this tax-related withholding, Tucker beneficially owned 731,225 common shares directly. He also reported indirect holdings of 51,465 shares in joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares held by his spouse.
Vaxart, Inc. disclosed that it has entered into a termination agreement with Britannia Pointe Grand Limited Partnership to end its headquarters lease at 170 Harbor Way, South San Francisco. The lease covers approximately 24,606 square feet and will now terminate effective May 15, 2026, instead of the original expiration date of March 31, 2029.
Vaxart will pay rent and reimbursable expenses through the termination date, but will not owe any termination fees or penalties. The change is part of the company’s ongoing efforts to identify cost reduction opportunities. Vaxart intends to relocate its headquarters and labs to one of its other offices in the South San Francisco area.
Vaxart, Inc. insider Michael Finney reported equity transactions in company stock. On December 4, 2025, he acquired 151,351 shares of common stock at a price of $0, reflecting the full vesting of previously granted restricted stock units. On the same date, 54,153 shares were disposed of at $0.37 per share, representing shares withheld by Vaxart to cover income tax obligations tied to the RSU vesting.
After these transactions, Finney beneficially owns 1,787,559 shares of Vaxart common stock directly, plus 100,000 shares held indirectly through the Lo Family Trust. The reported holdings also include 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Vaxart insider Michael Finney has filed a notice to sell up to 40,000 shares of VXRT common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $14,400.00 listed in the filing. The document also notes that 240,069,844 shares of the issuer’s stock are outstanding.
The 40,000 shares were originally acquired on 02/13/2018 in a private cash transaction from the issuer or an affiliate. In addition, the filing lists recent sales over the past three months, including 51,179 VXRT shares sold on 12/01/2025 for gross proceeds of $18,927.93. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Vaxart.
Vaxart, Inc. director reports open-market stock purchases. A Vaxart (VXRT) director bought 15,000 shares of common stock on 11/17/2025 at a price of $0.41 per share and an additional 5,000 shares at $0.407 per share, both coded as open-market purchases. Following these transactions, the director beneficially owns 124,125 shares of Vaxart common stock in direct ownership form. The report notes that the filing was submitted late due to delays in receiving EDGAR access codes.